Our news section contains recent news on neuroendocrine tumors, upcoming NANETS events and information, and people in our community. Have a suggestion? Please click here to contact us.

Jan 2017 NETwork Connection- Clinical Trials

Clinical Trials In the News:

On January 12, that the New England Journal of Medicine published the results of the NETTER-1 Phase III study evaluating efficacy and safety of Lutathera® (lutetium-177 dotatate), an investigational drug, in patients with advanced, progressive somatostatin receptor-positive midgut neuroendocrine tumors (“NETs”). 

2017 ASCO GI Preview

ASCO GI Header

The 2017 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium will run from Thursday, January 19 through Saturday, January 21 in San Francisco, California. The symposium will feature two sessions on neuroendocrine tumors (NETs), as well as poster presentations and an oral abstract presentation on NET research and therapy.

FDA approves new diagnostic imaging agent to detect rare neuroendocrine tumors

On June 1, 2016, the U.S. Food and Drug Administration (FDA) granted approval to Netspot, the first kit for the preparation of Gallium-68 dotatate positron emission tomography (68Ga-dotatate PET) imaging. Gallium-68 dotatate is a positron-emitting analogue of somatostatin, and the radioactive probe helps locate tumors in patients with somatostatin receptor-positive neuroendocrine tumors.

FDA grants a priority review of the new drug application for telotristat etiprate

On May 31, 2016, the U.S. Food and Drug Administration (FDA) granted a priority review of the new drug application for telotristat etiprate (Lexicon), and oral drug used to treat carcinoid syndrome. As the priority review status shortens the review process to 6 months from the standard 10 months, the FDA will decide whether to approve telotristat etiprate for commercial use by November 30, 2016.

Pancreas Journal Publishes Abstracts from the 2015 NANETS Annual Symposium

The 2015 NANETS Annual Symposium Abstracts are now in print in Pancreas 2016 Volume 45 #3, March issue. The abstracts can be viewed at no charge by clicking here to the Journal's website.

FDA approves new indication for Novartis drug Afinitor® for progressive, non-functional GI and lung neuroendocrine tumors (NETs)


On February 26, 2016, the U.S. Food and Drug Administration (FDA) approved everolimus (Afinitor®, Novartis) tablets for the treatment of adult patients with progressive, well-differentiated, non-functional neuroendocrine tumors (NETs) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic. Afinitor received a priority review designation providing a shortened review period for drugs that treat serious conditions and offer a significant improvement in safety or effectiveness.

2015 YI and NCIS Scholarship Recipients

Developing the next generation of clinicians and researchers in the field of neuroendocrine tumors (NETs) is an important objective of NANETS. This grant offers a platform to highlight and financially support the NET research conducted by junior investigators in the field.

2015 NCIS Recipient - Arvind Dasari, MD

The NCIS award focuses on supporting a clinical project as well as the investigator's potential to make future clinical contributions to the neuroendocrine tumor field.  Dr. Dasari is an ideal candidate and his research proposal and objectives show great potential.  This award is in honor of Edda Gomez-Panzani, MD for her dedication and work on behalf of patients living with neuroendocrine tumors.

Practice Changing Phase III Trials Presented at 2015 NANETS Symposium

The results of three recent, practice-changing Phase III clinical trials were presented for the first time in North America at the NANETS symposium which included: (1) TELESTAR (randomized Phase III trial of telotristat vs. placebo in patients with carcinoid syndrome), (2) NETTER-1 (randomized Phase III trial of 177-Lu-DOTATATE vs.

NANETS Members Elect New Leadership for 2016/17

I am pleased to announce the election results, and to both congratulate and extend a warm welcome to the new members of our Board of Directors, Advisory Board, and Nominating Committee.

The results of the 2016/17 elections are as follows: